Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mary Ann Gray is Director at Keros Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Jun 5, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
Mary Ann Gray has no open-market purchase on record since 2013. Sales in 3 of the 14 years since 2013.
Mary Ann Gray reported 0 open-market purchases and 4 sales since 2013; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2015 | — | $149K1×1 trade |
| 2014 | — | $389K1×1 trade |
| 2013 | — | $310K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Keros TherapeuticsKROS
2 disclosures · Jun 2026
Jun 3, 20267,142disclosed Jun 5
DetailsOfficial recordJun 3, 20267,433disclosed Jun 5
DetailsOfficial recordJan 2, 202690Kdisclosed Jan 5
DetailsOfficial recordAs of the latest filing on , Mary Ann Gray reported holding 12,392 shares of Keros Therapeutics (KROS), worth about $140K at the last close of $11 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Keros Therapeutics KROS | 12,392 | 12K direct | $11 | $140K | Jun 3, 2026 |
Is this Mary Ann Gray’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Mary Ann Gray reported 0 open-market purchases and 4 sales here, 2013 to 2015.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Jun 3, 2026, Mary Ann Gray reported holding 12,392 shares of Keros Therapeutics (KROS). At the last close of $11 on Nov 17, 2026, that is about $140K. This is the stake disclosed in filings, not a net worth.
Mary Ann Gray has no open-market purchase on record since 2013. Sales in 3 of the 14 years since 2013.
In SEC filings since 2013: no open-market purchase is on record; the latest open-market sale is from 2015.
Acadia Pharmaceuticals (ACAD), from 2013 to 2015: 0 purchases and 4 sales.